Neumora Therapeutics (NasdaqGS:NMRA) Earnings Call Presentation

NMRA-511 Phase 1b Study Results - NMRA-511 Phase 1b study is for Alzheimer's Disease (AD) Agitation [2] - The company is focused on redefining neuroscience drug development [4] - Alzheimer's disease affects approximately 7 million U S adults in 2024, and this number is expected to increase to 13 million by 2050 [12] - Over 70% of people with Alzheimer's Disease experience agitation at some point [12] - NMRA-511 demonstrated a 15 7-point reduction in CMAI total score at Week 8 [47] NMRA-511 Clinical Trial and Safety - In the NMRA-511 Phase 1b study, 40 participants were in the NMRA-511 group and 40 in the placebo group [45] - 45% of the NMRA-511 group were male, compared to 37 5% in the placebo group [45] - 67 5% of the NMRA-511 group were White, compared to 75% in the placebo group [45] - Protocol-defined medication non-adherence was observed in 17 5% of the NMRA-511 group [45] - The company plans to initiate a multiple ascending dose extension in 2026 to enable higher dosing [61]